News | January 01, 2025
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Exploring new opportunities within the fast-growing market of microfluidics
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Construction of the plant will commence in 2025 with first production expected to be in 2027
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
Subscribe To Our Newsletter & Stay Updated
